Evidence map›Paper›PMID 35300983›Full record

ArticleJournal of lipid research2022

Pulmonary surfactant protein B carried by HDL predicts incident CVD in patients with type 1 diabetes.

Baohai Shao, Janet K Snell-Bergeon, Laura L Pyle, Katie E Thomas, Ian H de Boer, Vishal Kothari, Jere Segrest, William S Davidson, Karin E Bornfeldt, Jay W Heinecke

Open access · goldAbstract read
In one paragraph

Article in Journal of lipid research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. The Remnant Lipoprotein Hypothesis of Diabetes-Associated Cardiovascular Disease.Arteriosclerosis, thrombosis, and vascular biology · 2022
    Review
  8. HDL, heart disease, and the lung.Journal of lipid research · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Baohai ShaoDepartment of Medicine, University of Washington, Seattle, WA, USA. Electronic address: bhshao@uw.edu.
Janet K Snell-BergeonBarbara Davis Center for Diabetes, University of Colorado Denver, Aurora, CO, USA.
Laura L PyleDepartment of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Katie E ThomasDepartment of Medicine, University of Washington, Seattle, WA, USA.
Ian H de BoerDepartment of Medicine, University of Washington, Seattle, WA, USA.
Vishal KothariDepartment of Medicine, University of Washington, Seattle, WA, USA.
Jere SegrestDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
William S DavidsonCenter for Lipid and Arteriosclerosis Science, Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH, USA.
Karin E BornfeldtDepartment of Medicine, University of Washington, Seattle, WA, USA.
Jay W HeineckeDepartment of Medicine, University of Washington, Seattle, WA, USA.
University of Washington · USUniversity of Cincinnati · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Colorado Denver · USVanderbilt University · US

Funding

ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI ALBERT, RICHARD K · 1985 to 2008
$52.6M
SPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI ROHIT N. KULKARNI · 1986 to 2026
$50.5M
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 1986 to 2026
$41.4M
Project 3 - HDL Structure/Function in LCAT Deficient HumansP01HL128203 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI W Sean Davidson · 2016 to 2026
$25.1M
Triglycerides, Diabetes and Cardiovascular DiseaseP01HL151328 · NHLBI · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 2020 to 2026
$19.6M
University of Colorado Anschutz Medical Campus DRCP30DK116073 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LORI SUSSEL · 2020 to 2026
$10.8M
Identifying new strategies for prevention of cardiovascular complications of diabetesR35HL150754 · NHLBI · UNIVERSITY OF WASHINGTON · PI BORNFELDT, KARIN E · 2020 to 2025
$6.2M
Apolipoprotein C3-loading of apolipoprotein B100 lipoproteins and cardiovascular disease in patients with type 1 diabetesR01HL161829 · NHLBI · UNIVERSITY OF WASHINGTON · PI HEINECKE, JAY W · 2022 to 2025
$3.3M
Complications and Comorbidities of Type 1 DiabetesR01HL113029 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SNELL-BERGEON, JANET KATHLEEN · 2013 to 2016
$2.9M
Structural basis for cardioprotective HDLR01HL149685 · NHLBI · UNIVERSITY OF WASHINGTON · PI BORNFELDT, KARIN E., HEINECKE, JAY W · 2020 to 2023
$2.8M
Discovery and validation of biomarkers of cardiovascular complications in type 1 diabetesR01DK116731 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI SNELL-BERGEON, JANET KATHLEEN, ZHANG, QIBIN · 2018 to 2020
$1.1M
NCRR NIH HHS M01 RR000051NHLBI NIH HHS P01 HL128203NHLBI NIH HHS P01 HL151328NHLBI NIH HHS R01 HL113029NHLBI NIH HHS R01 HL149685NHLBI NIH HHS R01 HL161829NHLBI NIH HHS R35 HL150754NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK036836NIDDK NIH HHS P30 DK116073NIDDK NIH HHS R01 DK116731
6 · The paper itself

Abstract

Atherosclerotic CVD is the major cause of death in patients with type 1 diabetes mellitus (T1DM). Alterations in the HDL proteome have been shown to associate with prevalent CVD in T1DM. We therefore sought to determine which proteins carried by HDL might predict incident CVD in patients with T1DM. Using targeted MS/MS, we quantified 50 proteins in HDL from 181 T1DM subjects enrolled in the prospective Coronary Artery Calcification in Type 1 Diabetes study. We used Cox proportional regression analysis and a case-cohort design to test associations of HDL proteins with incident CVD (myocardial infarction, coronary artery bypass grafting, angioplasty, or death from coronary heart disease). We found that only one HDL protein-SFTPB (pulmonary surfactant protein B)-predicted incident CVD in all the models tested. In a fully adjusted model that controlled for lipids and other risk factors, the hazard ratio was 2.17 per SD increase of SFTPB (95% confidence interval, 1.12-4.21, P = 0.022). In addition, plasma fractionation demonstrated that SFTPB is nearly entirely bound to HDL. Although previous studies have shown that high plasma levels of SFTPB associate with prevalent atherosclerosis only in smokers, we found that SFTPB predicted incident CVD in T1DM independently of smoking status and a wide range of confounding factors, including HDL-C, LDL-C, and triglyceride levels. Because SFTPB is almost entirely bound to plasma HDL, our observations support the proposal that SFTPB carried by HDL is a marker-and perhaps mediator-of CVD risk in patients with T1DM.

Indexed as

AtherosclerosisCardiovascular DiseasesDiabetes Mellitus, Type 1Pulmonary Surfactant-Associated Protein BCholesterol, HDLHumansProspective StudiesRisk FactorsTandem Mass SpectrometryCholesterol, HDLPulmonary Surfactant-Associated Protein BatherosclerosisCACTIcase-cohort designHDL proteomicsincident CVDMSparallel reaction monitoringplasma fractionationSFTPBsmoking status

Identifiers

PMID35300983
PMCPMC9010748
OpenAlexW4220998074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.